Clinical Trials · NCT04958109
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 16
- Start date
- Oct 2021
- Locations
- 1 site, United States
- Primary endpoint
- Oral Glucose Sensitivity Index (Kisspeptin-Placebo)